Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: What are the risks?

Internal Medicine Journal

Volumn 44, Issue 3, 2014, Pages 287-290

  Subramaniam, K ^a   Yeung, D ^b   Grimpen, F ^a   Joseph, J ^b   Fay, K ^b   Buckland, M ^b   Talaulikar, D ^a   Elijah, J ^a   Clarke, A C ^a   Pavli, P ^a   Moore, J ^b  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Biologicals; Hepatosplenic T cell lymphoma; Immunosuppression; Inflammatory bowel disease; Psoriasis

Indexed keywords

ASPARAGINASE; AZATHIOPRINE; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETANERCEPT; ETOPOSIDE; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MESALAZINE; METHOTREXATE; PREDNISONE; VINCRISTINE; BIOLOGICAL PRODUCT;

ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CASE REPORT; CHROMOSOME 14; CHROMOSOME 17P; CHROMOSOME 20; CHROMOSOME 7Q; CHROMOSOME 8Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME DELETION Y; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; CYTOGENETICS; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; FEVER; FLOW CYTOMETRY; GAMMA DELTA RECEPTOR GENE; GENE; GENE REARRANGEMENT; HEPATOSPLENIC T CELL LYMPHOMA; HEPATOSPLENOMEGALY; HUMAN; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; IMMUNOPHENOTYPING; INTESTINE RESECTION; ISOCHROMOSOME; KARYOTYPING; LETHARGY; LIVER BIOPSY; LIVER CANCER; LIVER SINUSOID; LUNG INFILTRATE; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; MALAISE; MALE; NEUTROPENIA; NEUTROPENIC SEPSIS; PANCYTOPENIA; PRIORITY JOURNAL; PSORIASIS; SEPSIS; SKIN BRUISING; SPLEEN CANCER; SPLEEN INFARCTION; T CELL LYMPHOMA; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION; CHEMICALLY INDUCED; LIVER NEOPLASMS; LYMPHOMA, T-CELL; RISK FACTOR; SPLENIC NEOPLASMS;

ADULT; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LYMPHOMA, T-CELL; MALE; RISK FACTORS; SPLENIC NEOPLASMS;

EID: 84896849512     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12363     Document Type: Article

References (11)

1. Vega F, Medeiros LJ, Gaulard P. Hepatosplenic and other gammadelta T-cell lymphomas. Am J Clin Pathol 2007; 127: 869-880.
2. Jaffe ES. Pathobiology of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2006; 1: 317-322.
3. Belhadj K, Reyes F, Farcet JP, Tilly H, Bastard C, Angonin R etal. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102: 4261-4269.
4. Tey SK, Marlton PV, Hawley CM, Norris D, Gill DS. Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen. Am J Hematol 2008; 83: 330-333.
5. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S etal. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124-131.
6. Konuma T, Ooi J, Takahashi S, Tomonari A, Tsukada N, Kobayashi T etal. Allogeneic stem cell transplantation for hepatosplenic gammadelta T-cell lymphoma. Leuk Lymphoma 2007; 48: 630-632.
7. Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14: 991-997.
8. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M etal. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41.
9. Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED. Hepatosplenic T-cell lymphoma in patients receiving TNF-a inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol 2011; 23: 1150-1156.
10. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013; 108: 99-105.
11. Drini M, Prichard PJ, Brown GJ, Macrae FA. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease. Med J Aust 2008; 189: 464-465.